Kezar Life Sciences, Inc. (KZR), a company focused on the development of clinical-stage biotechnology, announced on Monday a one-for-ten reverse stock split. This action is intended to help the company meet the minimum bid price requirement of $1.00 per share, necessary for maintaining its listing on The Nasdaq Capital Market. Trading of the company's shares on a post-split basis will commence on October 30.